Exporter

EN
FR
Efavirenz + lamivudine + tenofovir
Statut de médicament essentiel
Description générale
A fixed-dose combination of two nucleoside reverse-transcriptase inhibitors (NRTIs, lamivudine and tenofovir disoproxil fumarate) and a non-nucleoside reverse transcriptase inhibitor (NNRTI, efavirenz) for treatment of human immunodeficiency virus (HIV) disease.
INN
Efavirenz + lamivudine + tenofovir
Codes ATC
J05AR11
Type de médicament
Chemical agent
Historique des statuts LME
Équivalent thérapeutique pour
efavirenz + emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Wikipédia
Efavirenz + lamivudine + tenofovir
DrugBank
Efavirenz ,
Lamivudine ,
Tenofovir disoproxil
Recommandations
Section
Fixed-dose combinations of antiretrovirals
  • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified